Orexigen Therapeutics, Inc.

Orexigen Therapeutics, Inc. (United States) has no DMF, CEP or site registration linked in our records. 2 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Orexigen Therapeutics, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/orexigen-therapeutics-inc

Overview

Orexigen Therapeutics, Inc. was a biopharmaceutical company focused on developing pharmaceutical products for the treatment of obesity. The company's main product was Contrave, a combination drug that was intended to help patients with weight management. Orexigen faced financial challenges and eventually entered bankruptcy proceedings.

Therapeutic areas

ObesityWeight Management

FDA compliance signals

2 FDA enforcement records linked to this company.

  • recall — Class III2018-11-14

    Container packaging defect.

  • recall — Class III2018-08-22

    Defective Container: Customer complaints of punctures in the bottle.

For suppliers

Is this Orexigen Therapeutics, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.